Cwm LLC Raises Position in Natera, Inc. $NTRA

Cwm LLC boosted its stake in Natera, Inc. (NASDAQ:NTRA - Free Report) by 59.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 41,185 shares of the medical research company's stock after buying an additional 15,407 shares during the quarter. Cwm LLC's holdings in Natera were worth $6,958,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Bank of Jackson Hole Trust purchased a new position in Natera in the 1st quarter valued at about $29,000. Hilltop National Bank acquired a new stake in Natera in the 2nd quarter valued at about $33,000. Oliver Lagore Vanvalin Investment Group acquired a new stake in Natera in the 2nd quarter valued at about $36,000. Rakuten Securities Inc. raised its holdings in Natera by 117.8% in the 1st quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock valued at $31,000 after acquiring an additional 119 shares during the last quarter. Finally, TCTC Holdings LLC raised its holdings in Natera by 114.8% in the 1st quarter. TCTC Holdings LLC now owns 232 shares of the medical research company's stock valued at $33,000 after acquiring an additional 124 shares during the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Natera Price Performance

Shares of NASDAQ NTRA opened at $179.42 on Thursday. The company has a market capitalization of $24.63 billion, a P/E ratio of -93.94 and a beta of 1.74. The company has a 50 day simple moving average of $166.81 and a 200-day simple moving average of $157.80. Natera, Inc. has a 1 year low of $117.27 and a 1 year high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). The company had revenue of $546.60 million for the quarter, compared to analysts' expectations of $476.84 million. Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The business's revenue for the quarter was up 32.2% on a year-over-year basis. During the same period in the previous year, the business posted ($0.30) EPS. Natera has set its FY 2025 guidance at EPS. As a group, research analysts expect that Natera, Inc. will post -1.49 EPS for the current year.

Insider Activity at Natera

In related news, Director Rowan E. Chapman sold 2,750 shares of the stock in a transaction that occurred on Thursday, August 28th. The shares were sold at an average price of $166.99, for a total transaction of $459,222.50. Following the completion of the transaction, the director owned 6,015 shares of the company's stock, valued at approximately $1,004,444.85. This trade represents a 31.37% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Michael Burkes Brophy sold 3,045 shares of the stock in a transaction that occurred on Tuesday, July 29th. The stock was sold at an average price of $137.40, for a total transaction of $418,383.00. Following the transaction, the chief financial officer directly owned 65,430 shares of the company's stock, valued at $8,990,082. The trade was a 4.45% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 72,464 shares of company stock worth $10,963,125. Company insiders own 5.63% of the company's stock.

Analysts Set New Price Targets

A number of analysts have commented on NTRA shares. Morgan Stanley reiterated an "overweight" rating and issued a $195.00 price objective on shares of Natera in a report on Sunday, August 10th. Canaccord Genuity Group reiterated a "buy" rating and issued a $200.00 price objective on shares of Natera in a report on Tuesday. Stephens reiterated an "overweight" rating and issued a $183.00 price objective on shares of Natera in a report on Friday, August 15th. Barclays reiterated an "overweight" rating and issued a $210.00 price objective (up previously from $190.00) on shares of Natera in a report on Friday, August 8th. Finally, Royal Bank Of Canada set a $268.00 price target on shares of Natera and gave the stock an "outperform" rating in a report on Tuesday, September 2nd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Natera has an average rating of "Moderate Buy" and a consensus price target of $194.06.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.